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Abstract
Background: Diabetes is one of the major health concerns in the US. According to the National
Diabetes Statistics Report, about 13% adults in the U.S. had diabetes, and 34.5% of the U.S.
adults were categorized as prediabetic. An estimated cost of $327 billion were reported as
relevant to diagnosed diabetes in 2017 in the United States by the American Diabetes Association.
The virtual Diabetes Prevention Program (vDPP) was designed to address barriers that low
social-economic status participants faced when they were enrolled in a diabetes prevention
program. It used a digital platform to deliver courses, organize meetings and monitor health
outcomes, on the purpose of saving participants’ time and money. It also had community health
workers (CHW) to assist the implementation. This review aimed at identify approaches to
analyze the value of the vDPP economically.
Method: We explored two approaches to comparing vDPP costs with costs of previous similar
programs: cost effectiveness, which specifically interested in program costs per specified
behavior change, and cost benefit, which investigated both program costs and program benefits.
The health outcome we were interested in were body weight, HbA1c level and physical activity
level.
Results: The program costs were divided into two categories: fixed and recurrent, for easier
understanding and collecting. The program benefits were represented by medical cost savings,
which could be estimated based on health outcome changes, or compared with other similar
interventions.
Discussion: Comparing program costs existed studies with matched results was easier to
accomplished than collecting patient cost savings, on the aspect of showing program benefits.
However, the final decision is still pending due to the complexity of the analysis.
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Background
Diabetes is associated with numerous negative health consequences, and thus causes increased
health care expenditures and elevated burden on health systems. Based on the findings from the
American Diabetes Association’s Economic Costs of Diabetes in the U.S., the total estimated cost
of diagnosed diabetes in 2017 in the United States reached to $327 billion.1 And according to the
National Diabetes Statistics Report, an estimated 34.1 million adults aged 18 years or older in the
U.S. had diabetes in 2018, which formed 13% of all US adults.2 Moreover, a total of 88 million
adults were estimated to have prediabetes, and no significant change has been observed in the
age-adjusted prevalence of prediabetes since 2005.2 Prediabetes is when blood glucose levels are
higher than normal but not high enough for a diagnosis of diabetes. This means about 34.5% of
all US adults were at high risk of diabetes based on their fasting glucose or A1c level. Progress
from prediabetes to type 2 diabetes mellitus (T2DM) is preventable by pharmaceutical
(Metformin) and lifestyle approaches. In this paper we will be identifying an approach for
assessing cost effectiveness of an adapted lifestyle intervention.
The Diabetes Prevention Program (DPP) Research Group performed one of the most cited
lifestyle interventions for diabetes prevention, which has also been adopted and translated by
many later studies due to its effectiveness in preventing diabetes. Although it was a large study
with a sample size of 3,234, there were limitations regarding participant selection. Specifically,
the trial recruited participants at high risk for T2DM over 25 years old, who came from different
age groups and religions, but socioeconomic status of participants was not taken into
considerations.3 Socioeconomic status is an important factor of subjects’ ability to participant, as
low income individuals face barriers such as limited access to transportation, financial pressures
that may affect ability to fully respond to dietary and physical activity recommendations that are
6

not tailored to low income participants. Participants with low socioeconomic status often have
the main part of their life on making a living. They are also more willing to spend time on their
work and family, instead of considerations about improving health condition. In the virtual
Diabetes Prevention Program (vDPP), we are addressing the barriers by delivering the
intervention virtually. On top of that, a community-based study design allows us to address other
social barriers and unmet needs faced by low-income participants, such as healthy food access
and ability to meet physical activity guidelines.
As part of assessing the adapted vDPP, cost and cost-effectiveness are essential aspects of the
program evaluation, due to increasing constraints on health systems.4 Many cost-effectiveness
analyses of existed diabetes interventions, including the DPP, collected medical costs directly,
from self-reports or patients’ medical records, to estimate program effectiveness.5-7 The most
basic and significant components for medical cost collecting include, but are not limited to,
primary and secondary care utilization, prescribed medication costs and out-of-pocket payments,
if applicable. For the vDPP, two years of prospective collection of medical costs would allow the
strongest assessment of cost effectiveness, although other approaches are available. we identified
alternative methods to analyze the costs and effectiveness. In order to allow economic analysis of
the vDPP in comparison with other lifestyle interventions, we identified data collection needs for
the vDPP. Secondly, we also performed a literature review to develop a method to compare the
economic benefit of the vDPP with other studies. The review identified different approaches to
analyze the value of the vDPP, and guided development of an efficient data collection tool to
assist implementation.
Our decisions were made based on Table 1, which included the major types of economic
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analyses for scientific interventions. The development of a cost-benefit analysis, as well as a
cost-effectiveness analysis that will allow comparisons of costs of existing programs to the cost
of the vDPP in terms of the health outcomes they each produce, was the purpose of this review.
Specifically, we were interested in three different health outcomes, which allowed us to make a
fair evaluation on the economic benefit of the vDPP. These outcomes were body weight, HbA1c
level and physical activity of the participants. They were particularly important for this literature
review, because the primary outcome of the vDPP is change in body weight, and the HbA1c level
is also one of the justified diabetes classification standards that plays a significant role in most
diabetes related researches. However, researchers have found that emphasizing body weight too
much as a weight discrimination in diabetes prevention might lead to unintended consequences,
such as undermined mental health, a higher risk of diabetes and greater chances to gain
weight.8-10 Thus, it is reasonable and beneficial to also pay attention to weight control methods,
such as increasing physical activities, by the public in diabetes prevention.

Research Design and Methods
Intervention
The vDPP plans to enroll a total of 120 participants from New Haven and Ansonia/Derby,
forming 3 cohorts of 40 participants, each with 20 from both regions. Participants’ inclusion
criteria for the program are 1) Medicaid-eligible, 2) at least 18 years old at the time of enrollment,
3) English speaking and 4) scored 9 points or more in the CDC prediabetes screening test. In the
first 16 weeks, curriculum from the DPP lifestyle intervention will be delivered weekly to
participants using Incenta Health, a digital platform accessible via mobile devices. After the end
of curriculum delivery, participants will be contacted monthly by CHWs or nurses to check their
8

maintenance status until the one-year program ends.
As mentioned, we explored two approaches to comparing vDPP costs with costs of previous
similar programs: cost effectiveness, which specifically interested in program costs per specified
behavior change, and cost benefit, which investigated both program costs and program benefits.

Cost Effectiveness Analysis
Comparing program costs occurring during implementation with existed studies to see if the
vDPP cost less in achieving similar goals was one of the approaches we suggested. To develop
this method, we included program costs from vDPP and identified similar interventions for
comparison. The DPP focused on weight loss and physical activity goals for its lifestyle
intervention, which were 7% weight loss and ≥ 150 min/wk of activity that was similar in
intensity to brisk walking.11 We suggested the vDPP to use the same goals, in order to make a
fairer comparison. To compare the cost estimates from the DPP we adjusted the costs from 2000
USD to 2020 USD using the US Inflation Calculator based on the CPI data published by the U.S.
Labor Department's Bureau of Labor Statistics on April 13, 2021 to adjust for inflation and
calculate the cumulative inflation rate through March 2021.12
In order to define categories included for program costs, we looked at the literature in the topic
of cost and cost-effectiveness analysis of diabetes prevention programs that involved community
health workers to determine the specified cost list of program costs. Each category in the cost list
was then identified as fixed or recurrent to make data collection easier for investigators, and thus
capture all of the necessary cost associated with the program. Most of the publications were
results of broad searching through PubMed, Google Scholar and Centers of Disease Control and
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Prevention (CDC) database. To obtain the most up-to-date information and to keep the data valid
within the current social and research environment, the search period was mainly set from
January 2014 to January 2021, unless an older publication had higher academic significance. The
searching term included cost-effectiveness analysis, cost analysis, diabetes prevention and
community health workers. In addition to the publication database, we also reviewed materials
received from Health Equity Solutions, Inc. (HESCT) based on their professionalism in
community health workers.

Cost Benefit Analysis
Based on the fact that a negative change in patient costs represented a saving of health care
expenses, we wanted to perform the cost benefit analysis by collecting patient costs.13 Figure 1
represented an overall description of how each cost should be categorized and collected. In this
approach, we had to know not only the program costs, but also the estimated changes in
participant medical costs due to participation in the vDPP. However, because medical cost
estimation was so complicated, we developed two possible collection plans on top of direct
medical costs collection, which included change of costs approximation based on change of
outcomes, and interventions comparison. Database searching utilizing PubMed and citation
chaining from relevant articles. Searching terms for the second phase of review included diabetes
medical expenditure, physical activity, dietary and health outcome. To find cost-effectiveness
studies that used the same approach as ours, and to expand the searching scale, we applied
cost-effectiveness, community-based, and diabetes prevention, as well. The term searching was
followed by abstract review of listed publications to identify population, time frame, program
type and relevance of comparison. While strict inclusion criteria were not pre-specified, we
focused on diabetes prevention programs similar to the vDPP.
10

Results
Program Costs
A systematic review suggested that most diabetes interventions involving community health
workers identified four basic kinds of program costs, which were training costs, capital costs,
recurrent costs and overhead costs.14 According to the study design, we decided to divide the
program costs into two categories: fixed and recurrent. This is because we did not expect there
would be any overhead costs happening for our study, and we combined training costs and
capital costs in the fixed category to simplify the data collection process. The word “fixed” was
used to define costs that should only be recorded once during the whole study time, and would
never change afterwards. And the word “recurrent” represented any varied cost that would need
to be tracking all the way till the end of the vDPP. The expected costs before the actual initiation
of the study are summarized in Table 2, including costs happened in digital platform using,
electronic devices purchasing, training, supervisor salary, CHW & nurse salary, CHW & nurse
incurred costs, as well as costs for other supplies. It should be noted during program cost
collection that estimation of CHWs/nurses’ salaries was differentiated according to real scenarios.
In the vDPP research, the community health workers and nursers would spend all of their paid
time on the research, so we could simply collect their monthly salaries to capture the cost.
However, the assumption might not be held for the whole program, or many other studies. We
suggested that a more general way to estimate CHWs costs is to calculate their salaries by
tracking their work time.

Cost Comparison
Comparing with the DPP cost study, the program costs categories determined for the vDPP were
11

closest to direct medical costs of the DPP lifestyle intervention, in which they included costs for
core curriculum, materials, phone calls, supervised activity sessions, etc.5 Body weight, physical
activity and diet were the outcomes selected from the DPP for cost comparisons.15,16 The
comparison is shown in Table 3. Table 4 showcases the number of participants achieving the
target goals of the DPP, and corresponding program costs.

Medical Costs – Change of Costs Approximation via Outcomes
Medical costs can be approximated by multiplying costs related to unit health outcome change
from the actual data obtained from the vDPP about health outcome changes. Numerous
interventions were identified that estimated study effectiveness based on the changes of health
outcomes, such as HbA1c level and body weight.17-20, 21-28 Physical activity was also used as an
outcome, and medical cost savings were estimated using physical activity level as an indicator.
The possible physical activity capture approach would be walking steps per day and working-out
hours per week in the vDPP.29-35 Table 5 describes the comparison studies that evaluated costs by
the changes of those study outcomes.
Three relevant studies were identified that presented the relationship between type 2 diabetes
related health care costs change and percentage body weight change of participants, which were
comparable to the vDPP. Bell et al. specified in their observational study that a weight loss of
over 3% was associated with a diabetes-specific costs decrease of $440 per year, mainly driven
by lower outpatient visit and hospital visit rates.18 In Karkare et al’s study, 3%, 5% and 7%
weight loss were associated with approximately $189.16, $307.08 and $418.86 saving of annual
diabetes-related costs, relatively.20 Consistently, Mukherjee et al. also found that among obese
individuals, weight loss significantly led to decreased total diabetes-related health care costs over
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the subsequent year, where cost ratio was 0.96 (p<0.001).17 The sustained result supported the
hypothesis that we are capable to record participants’ body weight change and estimate the
medical cost savings in vDPP.
A research conducted in Netherlands by Rodríguez-Sánchez et al. demonstrated that a 1%-point
increase in HbA1c is associated with a 2.2% higher total care costs among patients with diabetes,
covering their 4-year study period from 2008 to 2011.22 To showcase the exact costs of HbA1c
control, Bansal et al. divided diabetic patients into two groups. Specifically, patients whose
HbA1c decrease less than 1% and who had a decrease larger or equal to 1% during the study
period were compared to each other on the aspect of total direct medical costs. During the
two-year period, a savings of $2503 was observed in the first year and $1690 was saved by
patients who had a HbA1c decrease ≥ 1% in the second year of follow up.27 It should be noted
that most studies investigating the costs of health care in relation to average glucose control
focused on treating the patients instead of preventing the disease. In other words, HbA1c level
control was a treatment, but not a prevention intervention that we will be conducting in vDPP.
No appropriate cost data indicating association between physical activity and diabetes medical
costs was found during the review, but there was a model that might be helpful in explaining the
change of medical costs accompanied with varied PA levels. In their study, Shah et al. used the
population attributable risk (PAR) percentage, calculated with the Levin’s formula, PAR% =
(pe(RR-1)/pe(RR-1) + 1)*100, and existing statistics datasets to estimate the range of cost of type
2 diabetes attributable to not meeting the physical activity Guidelines and physical inactivity in
the US in 2012.32 Here, pe represented the prevalence of exposure, which were not meeting the
physical activity guidelines and physical inactivity, and RR represented relative risk of diabetes
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incidence and the exposures. The cost estimation was achieved by multiplying together
diabetes-related costs per person and the number of T2D prevented, which should be the product
of calculated PAR% and total cases of Type 2 Diabetes in 2012.

Medical Costs – Citing from Comparable Interventions
Performing review on interventions with similar study designs, we selected best matched studies,
based on each of the health outcomes. They were displayed parallel to the vDPP according to
timelines (see Figures 2A-C). Figure 2A demonstrates how two lifestyle interventions, which had
body weight as their primary outcomes, were compared to the vDPP.

36, 37

Both interventions

adopted the curriculum from the DPP, just like the vDPP does. At the same time, they also had a
program implementation period of one year, which is the same as the vDPP’s study time frame.
The similarity made it possible for us to borrow their cost analysis on body weight changes to the
vDPP. Unfortunately, limited diabetes prevention interventions with HbA1c or physical activity
as the primary outcome were found to have similar study designs as the vDPP. Instead, we
compared diabetes treatment interventions for HbA1c costs, and physical activities interventions,
which had interests in diabetes and other related chronic diseases, to the vDPP’s timeline.38-42 All
of these studies delivered their own methods to improve participants’ health outcome, which
differed from the lifestyle curriculum we used in the vDPP. Lack of similarities in timelines was
another barrier for us to utilize their cost estimates in our analysis.

Discussion
To summarize, both cost comparison and cost saving estimations can perform well in providing
information on how the vDPP works on the aspect of costs and cost savings. Despite the
complexity of the review, the investigators will be able to collect program costs accurately, and
14

choose the best way to estimate either cost effectiveness (program costs for particular change
outcomes) or cost benefit (program costs and medical cost savings). Obviously, comparing
program costs to the DPP with matched results is much easier to accomplished than collecting
patient cost savings, on the aspect of showing program benefits. Lack of publications supporting
medical costs estimation also added complexity to cost-effectiveness analysis design. Overall,
the innovation and complication of the vDPP attach great significance to this review. As stated at
the beginning, this review not only proposed different approaches to cost-effectiveness analysis
of the vDPP, but also generated an efficient data collection tool to assist implementation. On top
of those, it was capable of helping investigators understand the progress of cost collection and
analysis more easily, as well. Another advantage of the review was that it drew people’s attention
to additional relevant behavior changes, over and above the original study primary outcome,
body weight. Like body weight, physical activity and calories restriction are also influential
factors of diabetes, but it is not emphasized as much as body weight is.43 As we mentioned, the
United States does not have many studies, linking physical activity or diet with diabetes
expenditures tightly. Even though epidemiologists have noticed the importance of physical
activity in reducing the risk of diabetes, limited efforts are made to propagandize it.
However, there were also several unavoidable limitations. One of the biggest ones was the
matching of study designs between the vDPP and the reviewed literatures, which were used for
cost saving estimation. The research team has proposed that the vDPP would only be conducted
for one year, during which we could monitor and access to participants’ data via the digital
platform freely. After that, no follow-up period has been designed. This impeded an accurate
approximation of program benefits, because most of the publications we found studied and
concluded following-up data of lifestyle interventions. The following-up data is significant in
15

cost-effectiveness analysis, because it tells us if program effects would be sustained, and how
costs would be changed after interventions as time goes by. It is common that lifestyle
interventions were only be capable of achieving positive cost saving many years after
implementations. If we could not understand how cost change patterns look like without the
forces of interventions, accuracy of our cost-effectiveness analysis would be limited.
Literature reviews normally suffer from massive loss of information during the searching stage
due to the publication bias that happened when we used publication databases as the only
evidence resource. The availability of evidence through published literature was confined, due to
publication restrictions, like study scale and completeness. It was very possible that studies that
had not reviewed or published yet held the information we needed. Researchers usually use
funnel plots to assess the publication bias in meta-analysis.44 Whereas, no tool was suggested as
an assessment method of the bias in our literature review. A greater scale of literature searching
is expected to mitigate such kind of selection bias.
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Appendix A.
Table 1 Economic Evaluation Types
Type of Analysis

Question Addressed

Measurement of Benefits

Cost Minimization Analysis

Can we do it for less?

None

Cost Effectiveness Analysis

Is the (natural) outcome worth the cost?

Natural units

Cost Utility Analysis

Are the quality adjusted life years (QALYs) worth the cost?

QALYs

Cost Benefit Analysis

Is there a reasonable return on investment?

Dollars

Figure 1 Mind Map
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Table 2 Program costs
Cost
Digital platform use
Fixed

Electronic devices purchase
Training fees
Supervisor salary

Recurrent

CHW & nurse salary
CHW & nurse incurred costs
Other Supplies

Table 3 Summary of DPP outcomes and costs
DPP Lifestyle (Knowler et al.)

Outcomes

24 week/16 session

1 yr (Mayer-Davis et al.)

DPP Metformin (Knowler et al.)
3 yr

1 yr (Mayer-Davis et al.)

3 yr

Body Weight

-6.5 ± 4.7 kg or -6.9 ± 4.5%

/

-4.5 ± 7.6 kg or -4.9 ± 7.4%

/

-2.1 kg

PA

224 ± 141 min/wk

/

227 ± 212 min/wk

/

/

energy intake -1897 kJ/d

energy intake -1235 kJ/d
/

(-294 kcal/d) and fat
intake -0.8%

/

Diet

/

(-452 kcal/d) and fat
intake -6.6%

HbA1c

/

/

no change of HbA1c

/

+0.1%

Cost per capita ($)1

/

1399/2103

2780/4178

1019/1532

2542/3821
26

1. Costs reported in 2000 USD/adjusted to 2020 USD

Table 4 Summary of DPP adherent results and costs
DPP Lifestyle (N=1079)1
24 week/16 session (Wing et al.)
Outcome Goals

end of intervention (3 yr) (Wing et al.)

participant achieved the
goal

Cost per participant achieved the
goal

participant achieved the
goal

Cost per participant achieved the
goal

n (%)1

2020 USD

n (%)1

2020 USD

7% Weight Loss

528 (49%)

$4,297.61 399 (37%)

$11,298.40

≥150 min/wk of
activity2

798 (74%)

$2,843.53 722 (67%)3

$6,243.85

Total cost

4

$2,269,137.00

$4,508,062.00

1. N=Total participant number in the intervention group; n=participant number achieved the goal
2. Using activities similar in intensity to brisk walking
3. 75% of participants who met PA goals at the end of the core curriculum achieved goals at the end of intervention; 50% of participants who did not meet PA goals at the end
of the core curriculum achieved goals at the end of intervention
4. Dollars were adjusted by the US Inflation Calculator, which uses the latest US government CPI data published on April 13, 2021 to adjust for inflation and calculate the
cumulative inflation rate through March 2021. The U.S. Labor Department's Bureau of Labor Statistics will release the Consumer Price Index (CPI) with inflation data for
April on May 12, 2021. https://www.usinflationcalculator.com/
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Table 5 Lists of publications on association between costs and health outcomes
Study

Year

Duration

Health Outcome
Measures

Study Design

Study Population

Costs Included in Estimation

Body Weight
≥ 18 years old
Mukherjee et al.

2016

12 months

percentage weight
change

cohort study

subgroup: obese individuals with no
previous cardiovascular disease

The gross covered payments for all health care
service or products, including the patients’ and
the payers’ portions of payment

≥ 18 years

Bell et al.

2014

2000-2010

percentage weight
change

cohort study

at least 1 non-insulin anti diabetic

The estimated costs to treat the patient based on

(NIAD) therapy prescription during the

charges billed for pharmacy and medical

patient identification period

services

required to be diagnosed with T2D.
Fridman et al.

2020

/

percentage weight

literature

change

review

Outpatient and inpatient medical costs, labs
/

costs and pharmacy costs (both all-cause and
diabetes-related)
All-cause and T2DM-related costs, including

Karkare et al.

2019

2010-2014

percentage weight
change

cohort study

patients with diabetes

mutually exclusive pharmacy services,
outpatient visits, emergency department (ED)
visits and inpatient visits

HbA1c
Elgart et al.

2019

2015-2016

percentage
HbA1c

≥ 18 years old
cohort study

Costs of hyperglycemia drug treatment
diagnosed with type 2 diabetes

28

have filled out a QUALIDIAB form
with HbA1c data
Rodríguez- Sánchez
et al. / the

2018

2008-2011

Netherlands

Oglesby et al.

2006

1998-2003

percentage
HbA1c

percentage
HbA1c

Total costs not necessarily related to diabetes
cohort study

diagnosed with type 2 diabetes

and devices cost

cohort study

individuals with continuous insurance

Diabetic Prescription Drugs and Total Diabetes

coverage

Attributable Costs, Such payments include both
payments by insurance companies as well as

diagnosed with type 2 diabetes
≥ 18 years old
April to
Aagren et al.

2011

September
2007

percentage
HbA1c

including GP treatment, hospitalization, drugs

cohort study

diagnosed with type 1 or type 2 diabetes
patients’ average HbA1c value had to
be ≥6%

payments by patients.
Overall medical and diabetes-related costs were
defined as the sum of office, inpatient,
outpatient, ER and other costs, such as costs
associated with laboratory tests, rehabilitation
facilities and nursing homes. Diabetes-related
costs included prescription refills and medical
claims coded with ICD-9-CM 250.xx.

diagnosed with type 2 diabetes
be at least 18 but under 75 years old
Juarez et al.

2013

2006-2009

percentage
HbA1c

cross sectional

Costs included direct medical expenses paid by

and cohort

be enrolled with medical and drug

the health plan: facility, physician services, and

study

coverage

pharmaceutical

have at least 1 HbA1c value at >9% in
2006

29

diagnosed with type 2 diabetes
Mata-Cases et al.

2020

/

HbA1c level

Modelling

(mmol/mol)

simulations

cared for by the Catalonian Health

Management costs and Direct costs

Institut in 2011 in Catalonia baseline
level of HbA1c
≥ 18 years old
had at least two A1C measurements
within 180–240 days of each other

Bansal et al.

2018

2009-2014

percentage
HbA1c

cohort study

with an initial A1C ≥ 9%
continuously enrolled with medical and
pharmacy benefits through a
commercial health insurance plan or

Total direct healthcare costs were computed by
summing the costs associated with all medical
and pharmacy claims. Total direct costs
included inpatient, outpatient (e.g., office visits,
outpatient surgery), emergency room (ER)
services, pharmacy (drugs and medical
supplies), insulin pump costs (not shown) and
blood glucose meter costs (not shown)

Medicare Advantage health plan
≥ 30 years old

Menzin et al.

2010

2002-2006

percentage
HbA1c

cohort study

diagnosed with type 2 diabetes

Costs per Study Patient for Diabetes Related
Hospitalizations

2 or more A1c values within 1 year of
each other during the study period
Physical Activity
Kato et al. /Japan

2013

10 years

Bueno et al.

2017

/

steps/day

Simulation

min/week;

cross sectional

frequency of

study

middle‐aged Japanese people
hypertensive and/or diabetic seniors

Categorized medical costs (total, diabetes,
stroke, etc.)
Annual expenditures of medicine use

30

walking (weekly)
Aoyagi et al. /Japan

2011

2000-2007

steps/day

Shah et al.

2016

/

min/week

cohort study
cross sectional
study

>=65 years old

Mainly as the outpatient

the US adults

The annual medical cost

40-65 years old
Fernandes et al.
/Brazil

2019

2014-2015

steps

cohort study

no diagnosis of previous cardiovascular
complications, no diabetes

The costs of medicine use

complications, no regular medication
use, and no physical disability
diagnosed with type 2 diabetes

scoring of
questionnaires
Codogno et al.
/Brazil

2011

/

based on

cross sectional

occupational,

study

sports and leisure

2018

2002-2013

minutes/week

individuals would have to present at

Laboratory tests; Medication (T2D, other);
consultation (Medical, Nursing)

least one-year complete medical records

and mobility
Xu et al.

≤ 75 years old

previous to the interview
cohort study

the US adults

The sum of total health care expenditure

31

Figure 2 Timelines
A. Cost-effectiveness analysis of diabetes prevention interventions with body weight as the primary outcome

Measurement timepoint
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B. Cost-effectiveness analysis of diabetes treatment interventions with HbA1c as the primary outcome

Measurement timepoint

33

C. Cost-effectiveness analysis of physical activity interventions

Measurement timepoint
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Appendix B
Table 6 Actual Costs as for April. 2020
Category

Amount (USD)

Digital Platform

$504/person-year

Electronic Devices Purchase for CHWs

N/A

Electronic Devices Purchase for participants $80/device
Training Fees

N/A

Office Supplies

N/A

Supervisor Salary

N/A

CHW Salary

$70,720/year

Nurse Salary

N/A

CHW Incurred Cost

N/A

Nurse Incurred Cost

N/A

Total

$140,800
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